Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H13NO3 |
Molecular Weight | 183.2044 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC(O)C1=CC(O)=C(O)C=C1
InChI
InChIKey=UCTWMZQNUQWSLP-UHFFFAOYSA-N
InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3
Molecular Formula | C9H13NO3 |
Molecular Weight | 183.2044 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Racepinephrine or racemic epinephrine is a mixture of levo and dextro isomers of epinephrine act as a nonselective agonist at adrenergic receptors. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, shortness of breath. Inhaled racepinephrine became available in September 2012 as a nonprescription treatment for bronchospasm based on a 1986 US Food and Drug Administration rule. Besides, racemic epinephrine relieves respiratory distress in hospitalized infants with bronchiolitis and is safe but does not abbreviate hospital stay. Morbidity associated with bronchiolitis as identified by parents persists for at least one week after hospital discharge in most infants.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331074 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22220172 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseFor temporary relief of mild symptoms of intermittent asthma: wheezing, tightness of chest, shortness of breath |
|||
Palliative | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg single, oral Overdose |
unknown, 2 years n = 1 Health Status: unknown Age Group: 2 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hypertension, Tachycardia... AEs leading to discontinuation/dose reduction: Hypertension (5.4%) Sources: Tachycardia (5.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertension | 5.4% Disc. AE |
50 mg single, oral Overdose |
unknown, 2 years n = 1 Health Status: unknown Age Group: 2 years Sex: M Population Size: 1 Sources: |
Tachycardia | 5.4% Disc. AE |
50 mg single, oral Overdose |
unknown, 2 years n = 1 Health Status: unknown Age Group: 2 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. | 1998 Apr 1 |
|
[Endoscopic mucosal resection of premalignant lesions of the upper gastrointestinal tract]. | 2001 Nov |
|
Cytotoxic effects of gingival retraction cords on human gingival fibroblasts in vitro. | 2004 Apr |
|
Cardiovascular responses of Chinook salmon (Oncorhynchus tshawytscha) during rapid anaesthetic induction and recovery. | 2004 Feb |
|
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. | 2004 Feb |
|
MAPK-dependent regulation of IL-1- and beta-adrenoreceptor-induced inflammatory cytokine production from mast cells: implications for the stress response. | 2004 Sep 21 |
|
[Experimental studies of rhizoma Astilbes chinensis on its effects in abirritation, blood activation, cough relieving and sputum elimination]. | 2006 Dec |
|
Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978. | 2006 Jan |
|
Stereospecificity of mushroom tyrosinase immobilized on a chiral and a nonchiral support. | 2007 May 30 |
|
Electrical nerve stimulation or ultrasound guidance for lateral sagittal infraclavicular blocks: a randomized, controlled, observer-blinded, comparative study. | 2008 Jun |
|
Analysis of efficacy of chiral adrenergic agonists. | 2008 Mar |
|
Caffeine and anaerobic performance: ergogenic value and mechanisms of action. | 2009 |
|
Simultaneous determination of epinephrine, uric acid and xanthine in the presence of ascorbic acid using an ultrathin polymer film of 5-amino-1,3,4-thiadiazole-2-thiol modified electrode. | 2009 Aug 4 |
|
The impact of platelet function or C-reactive protein, on cardiovascular events after an acute myocardial infarction. | 2009 Jul 7 |
|
High concentrations of dexmedetomidine inhibit compound action potentials in frog sciatic nerves without alpha(2) adrenoceptor activation. | 2010 Aug |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/show/NCT00817466
Bronchiolitis: 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline (racepinephrine) 20mg/ml diluted in 2ml NaCl. Maximum 12 inhalations/24 hours
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:01:50 UTC 2023
by
admin
on
Sat Dec 16 17:01:50 UTC 2023
|
Record UNII |
GR0L9S3J0F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
66887
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID80858965
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
4553
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
8059-19-6
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
SUPERSEDED | |||
|
CHEMBL1740
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
100000085694
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
GR0L9S3J0F
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
SUB10238MIG
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
4508
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
206-347-6
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
C76546
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
DB11124
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
33568
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
329-65-7
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
m4944
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | Merck Index | ||
|
6912-68-1
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
SUPERSEDED | |||
|
8060-13-7
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
SUPERSEDED | |||
|
838
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY | |||
|
GR0L9S3J0F
Created by
admin on Sat Dec 16 17:01:51 UTC 2023 , Edited by admin on Sat Dec 16 17:01:51 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |